Aggressiveness of care in a prospective cohort of patients with advanced NSCLC

被引:86
|
作者
Temel, Jennifer S. [1 ]
McCannon, Jessica [2 ]
Greer, Joseph A. [3 ]
Jackson, Vicki A. [4 ]
Ostler, Patricia [1 ]
Pirl, William F. [5 ]
Lynch, Thomas J. [1 ]
Billings, J. Andrew [4 ]
机构
[1] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Behav Med, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Dept Palliat Care, Boston, MA 02114 USA
[5] Massachusetts Gen Hosp, Dept Psychiat Psychooncol, Boston, MA 02114 USA
关键词
end-of-life care; nonsmall-cell lung cancer; hospice care; chemotherapy;
D O I
10.1002/cncr.23620
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Optimal end of life care of patients with terminal cancer is poorly understood. In this study, the aggressiveness of care is described in a cohort of patients with newly diagnosed advanced nonsmall-cell lung cancer (NSCLC). METHODS. Patients within 8 weeks of diagnosis of stage IIIb (with effusions) or IV NSCLC were enrolled in a study to examine the feasibility of involving palliative care services early in the provision of cancer care. Participants received standard oncology treatment and integrated palliative care. All patients were followed prospectively to assess anticancer therapy usage, hospital admissions, hospice utilization, and location of death. RESULTS. At the time of analysis, 40/46 (87%) of enrolled patients had died, with a median length of follow-up of 29.3 months. Aggressive care measures in the final month of life included rates of anticancer therapy (40%), emergency department visits (48%), and hospital admissions (50%). Sixty-five percent of patients received hospice care before death, with a median length of stay of 16 days. Patients with heightened baseline anxiety and mood symptoms were more likely to receive anticancer therapy at the end of life compared with those without such symptoms. CONCLUSIONS. This study demonstrates the frequent use of aggressive measures at the end of life among patients with advanced NSCLC in a tertiary care center, as shown by the number of patients receiving anticancer therapy within 30 days of death and brief utilization of hospice services. further research is needed to identify predictors of aggressive care and to develop interventions enhancing decision-making at the end of life.
引用
收藏
页码:826 / 833
页数:8
相关论文
共 50 条
  • [41] Health Care Utilization In Gout Patients: A Prospective Multicenter Cohort Study
    Singh, Jasvinder A.
    Bharat, Aseem
    Khanna, Puja
    Aquino-Beaton, Cleopatra
    Persselin, Jay E.
    Duffy, Erin
    Elashoff, David
    Khanna, Dinesh
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S852 - S853
  • [42] Counselling overweight and obese patients in primary care: a prospective cohort study
    Rodondi, Nicolas
    Humair, Jean-Paul
    Ghali, William A.
    Ruffieux, Christiane
    Stoianov, Rebecca
    Seematter-Bagnoud, Laurence
    Stalder, Hans
    Pecoud, Alain
    Cornuz, Jacques
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2006, 13 (02): : 222 - 228
  • [43] Symptom clusters (SCs) in advanced cancer patients (ACPs): A prospective cohort study
    Coecho Barata, Pedro Miguel
    Duarte De Oliveira, Sonia Margarida
    Santos, Filipa
    Filipe, Frederico
    Custodio, Maria Paula
    Cardoso, Alice
    Alves, Marta
    Papoila, Ana
    Barbosa, Antonio
    Lawlor, Peter G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [44] Changes in medication use in a cohort of patients with advanced cancer: The international multicentre prospective European Palliative Care Cancer Symptom study
    Paque, Kristel
    Elseviers, Monique
    Vander Stichele, Robert
    Pardon, Koen
    Hjermstad, Marianne J.
    Kaasa, Stein
    Dilles, Tinne
    De Laat, Martine
    Van Belle, Simon
    Christiaens, Thierry
    Deliens, Luc
    PALLIATIVE MEDICINE, 2018, 32 (04) : 775 - 785
  • [45] AGGRESSIVENESS OF END OF LIFE CARE FOR NEUROBLASTOMA PATIENTS
    Yanai, T.
    Miyata, K.
    Ochi, S.
    Saito, A.
    Kozaki, A.
    Ishida, T.
    Hasegawa, D.
    Kawasaki, K.
    Kosaka, Y.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S404 - S404
  • [46] Chemotherapy for palliation and 'best supportive care' in advanced NSCLC
    Cullen, M
    LUNG CANCER: CURRENT TOPICS, 2001, : 361 - 366
  • [47] Aggressiveness of care at the end of life in children with cancer: A nationwide cohort study
    Cardoso, A.
    Martins Branco, D.
    Lacerda, A.
    Gomes, B.
    Lopes, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Prognostic features in NSCLC patients with ECOG-PS 2-4: A prospective cohort study
    De Castro, G., Jr.
    Souza Borges, A. P.
    Das Neves, W.
    Lopez, R.
    Cunha, M. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S918 - S918
  • [49] Palliative care and catastrophic costs in Malawi after a diagnosis of advanced cancer: a prospective cohort study
    Bates, Maya Jane
    Gordon, Miriam R. P.
    Gordon, Stephen B.
    Tomeny, Ewan M.
    Muula, Adamson S.
    Davies, Helena
    Morris, Claire
    Manthalu, Gerald
    Namisango, Eve
    Masamba, Leo
    Henrion, Marc Y. R.
    MacPherson, Peter
    Squire, S. Bertel
    Niessen, Louis W.
    LANCET GLOBAL HEALTH, 2021, 9 (12): : E1750 - E1757
  • [50] Erlotinib as single agent in patients (p) with advanced or metastatic NSCLC:: A multivariate analysis in a prospective study.
    Pallares, C.
    Paz-Ares, L.
    López-Picazo, J.
    Pérez-Carrión, R.
    Montes, A.
    López-Vivanco, G.
    De Castro, J.
    Cobo, M.
    Velasco, A. García
    Regueiro, P.
    Massutí, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 409S - 409S